Mega Lifesciences Balance Sheet Health
Financial Health criteria checks 6/6
Mega Lifesciences has a total shareholder equity of THB9.2B and total debt of THB168.7M, which brings its debt-to-equity ratio to 1.8%. Its total assets and total liabilities are THB13.5B and THB4.3B respectively. Mega Lifesciences's EBIT is THB3.3B making its interest coverage ratio -73.9. It has cash and short-term investments of THB2.9B.
Key information
1.8%
Debt to equity ratio
฿168.75m
Debt
| Interest coverage ratio | -73.9x |
| Cash | ฿2.92b |
| Equity | ฿9.24b |
| Total liabilities | ฿4.29b |
| Total assets | ฿13.53b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: MEGA's short term assets (THB9.6B) exceed its short term liabilities (THB3.9B).
Long Term Liabilities: MEGA's short term assets (THB9.6B) exceed its long term liabilities (THB409.0M).
Debt to Equity History and Analysis
Debt Level: MEGA has more cash than its total debt.
Reducing Debt: MEGA's debt to equity ratio has reduced from 20.1% to 1.8% over the past 5 years.
Debt Coverage: MEGA's debt is well covered by operating cash flow (1165.2%).
Interest Coverage: MEGA earns more interest than it pays, so coverage of interest payments is not a concern.